Hennion & Walsh Asset Management Inc. Buys Shares of 308,457 Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. purchased a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 308,457 shares of the company’s stock, valued at approximately $1,697,000.

A number of other large investors have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares during the period. Geode Capital Management LLC grew its holdings in shares of Taysha Gene Therapies by 3.5% during the 2nd quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company’s stock worth $8,765,000 after purchasing an additional 128,840 shares during the period. Rhumbline Advisers increased its position in shares of Taysha Gene Therapies by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock worth $539,000 after purchasing an additional 27,794 shares during the last quarter. Prudential Financial Inc. raised its holdings in Taysha Gene Therapies by 50.5% in the 2nd quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after buying an additional 7,650 shares during the period. Finally, XTX Topco Ltd lifted its position in Taysha Gene Therapies by 57.9% in the second quarter. XTX Topco Ltd now owns 320,737 shares of the company’s stock valued at $741,000 after buying an additional 117,608 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Sean P. Nolan sold 136,789 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $649,747.75. Following the completion of the transaction, the chief executive officer owned 2,949,569 shares in the company, valued at $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kamran Alam sold 78,968 shares of the stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer directly owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is currently owned by company insiders.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $4.31 on Thursday. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The company has a fifty day simple moving average of $4.56 and a two-hundred day simple moving average of $4.62. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -12.68 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The company had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $1.89 million. As a group, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on TSHA. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Wall Street Zen upgraded Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Finally, The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $11.09.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.